Observational Study on the Patient's Ability to Use a Digital Platform in Heart Failure

Observational Study on the Patient's Ability to Use a Digital Platform in Heart Failure

Heart Failure has a global prevalence of 1 to 3% in the adult population with an incidence of 1 to 20 cases per 1,000 people. Furthermore, HF is often associated with a number of comorbidities (anaemia, arrhythmias, depression, hyperuricemia, coronary heart disease etc.), which greatly deteriorates the patient's quality of life.

Despite the development of specific drugs, HF has a very high mortality rate, and it is the first cause of unscheduled income. An increase of 50% of these incomes is expected in the next 25 years.

In this context, the use of digital tools/platforms that allow remote monitoring of patients and that facilitate telemedicine have shown potential to improve treatment adherence and facilitate continued therapeutic education, improving clinical results with savings in time and associated costs.

This study focuses on studying the ability of heart failure patients with reduced ejection fraction (EF≤40%) to use a digital platform through an application installed on the patient's smartphone.

This is an observational, prospective, single-center study. The protocol and informed consent document have been reviewed and approved by the Ethical Committee and the study will be performed in accordance with the Declaration of Helsinki

Inclusion Criteria:

• Patients aged 18 years or older
• Informed Consent is obtained from the patient
• Patients diagnosed with heart failure with reduced ejection fraction (EF≤40%)
• Patients who extensively use a smartphone.

Exclusion Criteria:

• Patients who will not be able to commit to carrying out the follow-ups or do not have adequate technological skills.
• Patients with inability to give adequately the informed consent.